The U.S. spent $99 billion on both oral and clinician-administered cancer therapies in 2023, according to a report published in April by analytics firm IQVIA. As cancer drug prices continue to increase, spending is projected to grow.
The Latest
Daniel Nikcevich, MD, saw a boat heading straight for him during a fishing trip in rural Minnesota.
Rochester, Minn.-based Mayo Clinic has broken ground on a $9 million cancer center expansion at its New Prague, Minn., medical campus.
Along with the premarket approval of Siemens' 3D breast-imaging technology, the FDA approved seven oncology and hematology drugs in September.
Six U.S. health systems and cancer centers have joined the recently launched Together for Supportive Cancer Care consortium alongside more than 30 research institutions and advocacy groups with the aim to make supportive cancer care the standard of care.
Michel Sadelain, MD, PhD, a CAR-T therapy innovator and one of the world's top immunologists, has left New York City-based Memorial Sloan Kettering Cancer Center for two new roles at Columbia University Irving Medical Center, also in New York City.
From 2012 to 2021, breast cancer incidence has risen 1%, with steep increases among young women and Asian American/Pacific Islander women, according to the American Cancer Society.
Moffitt Cancer Center patients will soon have access to on-demand virtual care services.
An AI-empowered blood test was able to more reliably identify ovarian cancer by detecting DNA fragments and protein biomarkers, according to a study published Sept. 30 in the American Association for Cancer Research's journal, Cancer Discovery.
The FDA's Oncologic Drugs Advisory Committee has voted to restrict the use of nivolumab and pembrolizumab immunotherapy drugs based on the programmed death-ligand 1 expression levels of patients, according to a Sept. 30 Medscape report.